D2 Derma Europe

D2 Derma is a clinical-stage biotechnology company based in Denmark that specializes in the development of next-generation topical treatments for chronic inflammatory skin diseases. The company's primary focus is on creating potent vitamin D3 analogs, such as its lead candidate D2-001, which are designed to maximize local therapeutic effects in the skin while minimizing systemic absorption and associated side effects like hypercalcemia. D2 Derma targets significant unmet needs in the psoriasis and atopic dermatitis markets by providing safer, more effective long-term topical options. The firm leverages deep expertise in vitamin D chemistry to advance its dermatological pipeline through clinical trials.